Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Factor VIII Prior Auth Coverage | Open…
    Ask Trek AI about this page
    CurrentZing HealthPolicy 5894-D

    Medicare Part B Step Therapy Factor VIII Products

    Customize your policy alerts

    Sign up for zing_health Policy 5894-D alerts

    Get alerted when Policy 5894-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage and prior authorization for preferred and non-preferred recombinant Factor VIII products under an Advanced Biosimilars First step-therapy program. It applies to members who are new to treatment with a non-preferred product and establishes clinical exception pathways for non-preferred therapy.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Factor VIII Products
    Policy CodePolicy 5894-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit clinical information supporting the requested non-preferred product and the applicable exception pathway through the prior authorization review process.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Preferred Factor VIII products
    6Non-preferred Factor VIII products
    365 daysPrior-use lookback
    2Clinical exception pathways

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Non-Preferred Product Exceptions

    Non-preferred product exception criteria

    Coverage for the non-preferred product is provided when either of the following criteria is met.

    ONE of the following

    • Prior treatment with requested product: Member has received treatment with the requested non-preferred Factor VIII product.Within the past 365 days
    • Inadequate response or intolerance to preferred products: Member has a documented inadequate response or intolerable adverse event with all preferred Factor VIII products.All preferred products

      Documentation is required.

    Prior Authorization and Step-Therapy Requirements

    Prior Authorization

    Clinical Prior Authorization May Apply

    Preferred or formulary status does not eliminate clinical prior authorization review. Verify whether clinical prior authorization is required before treatment, including for preferred products.

    Prior Authorization

    Non-Preferred Product Exception Review

    Prior authorization is required for coverage of a non-preferred Factor VIII product. The review evaluates clinical circumstances that exclude use of the preferred products and may consider the member’s previous use of the requested product.

    • Preferred products: Afstyla, Kovaltry, and Nuwiq.
    • Non-preferred products: Advate, Kogenate FS, Novoeight, Recombinate, Xyntha, and Xyntha Solofuse.
    Step Therapy

    Preferred-Product Step Therapy Required

    When requesting a non-preferred product for an indication that is FDA-approved for a preferred product, step-therapy requirements apply. Coverage requires the member to meet an applicable exception pathway.

    • The program applies to members requesting treatment for an indication FDA-approved for a preferred product.
    • The program applies to members who are new to treatment with a non-preferred product for the first time.

    Unsupported block type: documentationつcallout

    Documentation Required

    Submit Prior Authorization Support

    Submit clinical information supporting the requested Factor VIII product and the applicable exception pathway with the prior authorization request.

    • Include the requested product and the indication being treated.
    • Provide records supporting qualifying prior use or inadequate response/intolerance to all preferred products, as applicable.
    Denial Risk

    Denial Risk: Exception Criteria Not Met

    A non-preferred product may be denied when the submitted documentation does not establish a qualifying clinical circumstance that excludes use of the preferred products or otherwise satisfy an exception pathway.

    • Coverage requires either treatment with the non-preferred product within the past 365 days or inadequate response/intolerable adverse events with all preferred products.
    Denial Risk

    Denial Risk: No Qualifying History

    Denial risk is increased when neither qualifying prior use of the requested non-preferred product nor documented inadequate response or intolerance to all preferred products is established.

    • Confirm the prior-use history falls within the past 365 days.
    • If relying on treatment failure or intolerance, document the outcome for all preferred products.

    Policy Background

    This policy applies to Medicare Part B Advanced Biosimilars First coverage and prior authorization for recombinant Factor VIII replacement products. It addresses treatment for FDA-approved indications covered by the preferred products and applies to members who are new to treatment with a non-preferred product. The program prioritizes preferred Factor VIII products and allows coverage of a non-preferred product when a qualifying clinical exception is established, including prior use within the past 365 days or documented inadequate response or intolerable adverse events with all preferred products.

    Program Terms

    New to treatment with a non-preferred product
    DefinitionA member receiving a non-preferred Factor VIII product for the first time under this program.
    Clinical exception
    DefinitionA review pathway that determines whether clinical circumstances exclude use of preferred products or whether the member has previously used the requested non-preferred product.
    Qualifying prior useThe member received treatment with the requested non-preferred product within the past 365 days.
    Preferred-product exceptionThe member has a documented inadequate response or intolerable adverse event with all preferred products.

    Initial Non-Preferred Therapy

    Initial non-preferred therapy

    This program applies to members who are new to treatment with a non-preferred product for the first time. For an indication that is FDA-approved for the preferred product, coverage of the non-preferred product requires one of the following exceptions.

    ONE of the following

    • Prior treatment with requested product: Member has received treatment with the requested non-preferred Factor VIII product.Within the past 365 days
    • Inadequate response or intolerance to preferred products: Member has a documented inadequate response or intolerable adverse event with all preferred Factor VIII products.All preferred products

      Documentation is required.

    Preferred Product Pathway

    StepPreferred product pathwayNon-preferred product exception
    1Use a preferred Factor VIII product for treatment of an indication that is FDA-approved for the preferred product.Covered when the member received the requested non-preferred product within the past 365 days, or has a documented inadequate response or intolerable adverse event with all preferred products.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Factor VIII Products
    Policy CodePolicy 5894-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit clinical information supporting the requested non-preferred product and the applicable exception pathway through the prior authorization review process.
    SourceLink
    On This Page
    Non-Preferred Product ExceptionsPrior Authorization and Step-Therapy RequirementsPolicy BackgroundProgram TermsInitial Non-Preferred TherapyPreferred Product Pathway